Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severely Active Psoriatic Arthritis Subjects With Inadequate Response to Disease Modifying Anti-Rheumatic Drug Therapy

Inclusion Criteria: * Moderate to severe PsA * Inadequate response to DMARD therapy * Corticosteroid stable dose \<=10 mg QD * DMARDs must have been taken for 3 months and stable dose for 4 weeks * MTX maximum dose = \<=30 mg/week * Active chronic plaque PS or documented history of chronic plaque PS Exclusion Criteria: * No other active skin disease